Recombinant dog fur and scurf allergen fusion protein and application thereof

By recombining multiple dog flange allergen fusion proteins, the problem of large differences between existing extracts is solved, and the accurate diagnosis and treatment of dog flange allergens is achieved, ensuring the consistency of product quality.

CN119019567APending Publication Date: 2024-11-26宁波博肽生物技术有限公司
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410854781.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing dog fur dander allergen extracts have large batch differences due to source differences, making it difficult to achieve large-scale and commercial preparation, affecting diagnostic accuracy and reliability.

Method used

Recombinant dog fur dander allergen fusion protein, containing a variety of known allergens, such as Can f 1, Can f 2, Can f 4, Can f 6, Can f 3, Can f 5, Can f 7, Can f 8. Expression and purification in E. coli by gene recombination and expression techniques for preparation of products for diagnosis and treatment.

Benefits of technology

It solves the problem of batch differences, improves the accuracy and reliability of the test results, ensures the consistency of product quality, and is suitable for the diagnosis and treatment of dog fur dander allergens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019567A_ABST
    Figure CN119019567A_ABST
Patent Text Reader

Abstract

The invention is applicable to the technical field of recombinant proteins, and provides a recombinant dog fur and dandruff allergen fusion protein and application thereof, and the amino acid sequence of the dog fur and dandruff allergen fusion protein is as shown in SEQ ID No.1; preferably, the nucleotide sequence of the recombinant dog fur and dandruff allergen fusion gene is as shown in SEQ ID No. 10. The recombinant fusion protein disclosed by the invention is fused with four known dog fur and scurf allergens, Can f3 serum albumin, Can f5 arginine esterase, Can f7 epididymal-free secretory protein E1 and Can f8 cysteine-inhibiting protease proteins, wherein the dog fur and scurf allergens belong to a lipid transport protein family. The method solves the problems of large batch difference of the existing natural dog fur and scurf allergen raw materials and inaccurate detection results caused by high content or lack of partial allergens, ensures the batch consistency, controls the product quality, and has more accurate and reliable detection results.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of recombinant proteins, in particular to a recombinant dog dander allergen fusion protein and application thereof. Background Art

[0002] Allergies to pets (dogs, cats) affect 10%-20% of the world's population, and as these proportions increase, this will become an increasingly serious public health problem. Considering that dog and cat allergens are easily detected even in households without pets, there is an urgent need to accurately diagnose and treat patients to reduce the morbidity and mortality caused by contact. The current raw materials for diagnosing dog allergies mainly use natural dog hair and natural extracts from dog epithelium as raw materials for the development of diagnostic reagents. With the analysis of the sensitive components of individual allergenic proteins by molecular biology and proteomics, the detection rate of diagnosis has been significantly improved; to date, 8 dog dander allergens have been jointly identified by the World Health Organization and the International Society of Immunology, namely Can f 1, Can f 2, Can f 4 and Can f 6, four dog dander allergens known to belong to the lipid transport protein family, Can f 3 serum albumin, Can f 5 arginine esterase, Can f 7 immune epididymal secretory protein E1, and Can f 8 cysteine ​​protease inhibitor protein.

[0003] Existing dog dander allergen extracts are enriched from dog dander and dog epithelium. Due to the differences in the origins of different dog species and individuals, naturally extracted dog dander allergens have large differences in the content of the main dog allergens Can f 1 and Can f 5, which makes the developed dog dander allergen immunoblot detection kit have large batch differences, and the amount of natural extraction is small, making it difficult to carry out large-scale and commercial preparation. Summary of the invention

[0004] The object of the present invention is to provide a recombinant dog dander allergen fusion protein and its application to solve the problems in the above-mentioned background technology.

[0005] To achieve the above objectives, the present invention provides the following technical solutions: In a first aspect, the present invention provides a recombinant dog dander allergen fusion protein, the amino acid sequence of which is shown in SEQ ID No.1.

[0006] Preferably, the dog dander allergen fusion protein comprises the dominant sequence allergen lipocalin Canf 1, the amino acid sequence of which is shown in SEQ ID No.2; the dominant sequence allergen lipocalin Can f2, the amino acid sequence of which is shown in SEQ ID No.3; the dominant sequence allergen serum albumin Can f 3, the amino acid sequence of which is shown in SEQ ID No.4; the dominant sequence allergen lipocalin Can f 4, the amino acid sequence of which is shown in SEQ ID No.5; the dominant sequence allergen arginine esterase Can f 5, the amino acid sequence of which is shown in SEQ ID No.6; the dominant sequence allergen lipocalin Can f 6, the amino acid sequence of which is shown in SEQ ID No.7; the dominant sequence allergen immune epididymal secretory protein E1 Can f 7, the amino acid sequence of which is shown in SEQ ID No.8; and the dominant sequence allergen cysteine ​​protease inhibitor Can f 8, the amino acid sequence of which is shown in SEQ ID No.9.

[0007] Preferably, the nucleotide sequence of the recombinant dog dander allergen fusion gene is shown as SEQ ID No.10.

[0008] Preferably, the recombinant expression plasmid of the recombinant dog dander allergy allergen fusion gene nucleotide is pET-22b(+).

[0009] Preferably, the expression host used by the recombinant plasmid is Escherichia coli OrigamiB (DE3).

[0010] The second aspect of the present invention provides a method for preparing the dog dander allergen fusion protein according to the first aspect of the present invention, comprising the following steps:

[0011] Step (1), synthesizing a dog dander allergen fusion gene;

[0012] Step (2), after cloning the recombinant plasmid of step (1), constructing a recombinant expression plasmid pET-22b(+)-Can by homologous recombination, and verifying the correctness of its sequence;

[0013] Step (3), transfecting the recombinant expression plasmid of step (2) into the Escherichia coli expression host OrigamiB (DE3);

[0014] Step (4), expressing the recombinant dog dander allergen fusion protein in a prokaryotic expression medium using the strain of step (3);

[0015] Step (5), purifying the bacterial cells of step (4) by nickel column to obtain the recombinant dog dander allergen fusion protein;

[0016] Step (6), performing protein quantification and activity detection on the recombinant dog dander allergen fusion protein of step (5);

[0017] Step (7), storing the recombinant dog dander allergen fusion protein of step (6).

[0018] The third aspect of the present invention provides a use of the recombinant dog dander allergen fusion protein according to the first aspect of the present invention, wherein the recombinant dog dander allergen fusion protein can be used for dog dander desensitization treatment.

[0019] Preferably, the dog dander allergen fusion protein can be used as an immunological diagnostic reagent or an allergen detection diagnostic kit.

[0020] Preferably, the recombinant dog dander allergen fusion protein can be used to prepare a semi-quantitative dog dander allergen-specific IgE antibody detection kit, which includes a sample diluent containing a CCD blocker, a high-activity allergen membrane strip, an alkaline phosphatase-labeled mouse anti-human Ig E antibody, a substrate solution, a stop solution, a cleaning solution, and a quality control product.

[0021] Preferably, the IgE antibody detection kit uses the indirect method principle to perform allergen detection on an immunoblotting platform, and the entire reaction is automatically run on an automatic protein blotting instrument.

[0022] The present invention has at least the following beneficial effects:

[0023] The present invention provides a recombinant dog dander allergen fusion protein and application thereof. The recombinant fusion protein fuses four known dog dander allergens belonging to the lipocalin family, namely Can f 1, Can f 2, Can f 4 and Can f 6, serum albumin Can f 3, arginine esterase Can f 5, epididymal secretory protein E1 Can f 7 and cysteine ​​protease inhibitor Can f 8, thereby solving the problems of large batch differences of existing natural dog dander allergen raw materials and inaccurate detection results caused by excessive or missing content of some allergens. The present invention ensures batch consistency, controls product quality and makes detection results more accurate and reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is the SDS-PAGE electrophoresis diagram for the expression and identification of the dog dander fusion protein before and after induction;

[0025] Figure 2 This is the result of fusion protein purification;

[0026] Figure 3 This is a Western blot verification image of the dog dander allergen fusion expression protein. DETAILED DESCRIPTION

[0027] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] The present invention provides a fusion protein for recombinant dog dander allergens, comprising all core antibody binding peptides of currently known dog dander allergens, including all antibody recognition antigen peptides of Can f 1, Can f 2, Can f 4, Can f 6, Can f 3, Can f 5, Can f 7, and Can f 8.

[0029] The present invention adopts the following technical solution:

[0030] A recombinant dog dander allergy allergen fusion protein, the amino acid sequence of the recombinant dog dander allergen fusion protein is as shown in SEQ ID No.1; it also comprises a dominant sequence allergen lipid transport protein Can f 1 selected from the following amino acid sequence (SEQ ID No.2); a dominant sequence allergen lipid transport protein Can f 2 selected from the following amino acid sequence (SEQID No.3); a dominant sequence allergen serum albumin Can f 3 selected from the following amino acid sequence (SEQ ID No.4); a dominant sequence allergen lipid transport protein Can f 4 selected from the following amino acid sequence (SEQ ID No.5); a dominant sequence allergen arginine esterase Can f 5 selected from the following amino acid sequence (SEQ ID No.6); a dominant sequence allergen lipid transport protein Can f 6 selected from the following amino acid sequence (SEQ ID No.7); a dominant sequence allergen immune epididymal secretory protein E1 Can f 7 selected from the following amino acid sequence (SEQ ID No.8); and a dominant sequence allergen cysteine ​​protease inhibitor Can f 8 selected from the following amino acid sequence (SEQ ID No.9).

[0031] After codon optimization, the nucleotide sequence of the recombinant dog dander allergen fusion gene is shown in SEQ ID No.10.

[0032] According to some embodiments, the expression vector used by the recombinant plasmid is pET-22b(+).

[0033] According to some embodiments, the expression host used by the recombinant plasmid is Escherichia coli OrigamiB (DE3).

[0034] The method for preparing the above dog dander allergen fusion protein comprises the following steps:

[0035] (1) The above-mentioned dog dander allergen fusion gene is artificially synthesized;

[0036] (2) After cloning the recombinant plasmid of step (1), a recombinant expression plasmid pET-22b(+)-Can was constructed by homologous recombination, and the correctness of its sequence was verified;

[0037] (3) transfecting the recombinant expression plasmid of step (2) into the Escherichia coli expression host OrigamiB (DE3);

[0038] (4) expressing the recombinant dog dander allergen fusion protein in a prokaryotic expression medium using the strain obtained in step (3);

[0039] (5) Purifying the bacterial cells in step (4) by nickel column to obtain the recombinant dog dander allergen fusion protein;

[0040] (6) performing protein quantification and activity detection on the recombinant dog dander allergen fusion protein of step (5);

[0041] (7) Preserving the recombinant dog dander allergen fusion protein of step (6).

[0042] The method of the present invention can prepare a fusion protein of eight component allergens with only one expression, which can prevent inaccurate results caused by excessive or missing content of some allergens and improve the accuracy and stability of product detection.

[0043] The above-mentioned dog dander allergen fusion protein can be applied to dog dander or pet desensitization treatment, and can be specifically applied in immunological diagnostic reagents or allergen detection diagnostic kits. For example, a semi-quantitative dog dander allergen-specific IgE antibody detection kit can be prepared, including a sample diluent containing a CCD blocker, a highly active allergen membrane strip, an alkaline phosphatase-labeled mouse anti-human Ig E antibody, a substrate solution, a stop solution, a cleaning solution, and a quality control product. The indirect method principle is used to perform allergen detection on an immunoblotting platform, and the entire reaction is automatically run on an automatic protein blotting instrument:

[0044] (1) Preparation of cleaning solution, alkaline phosphatase-labeled mouse anti-human Ig E antibody, substrate solution, stop solution, and deionized water;

[0045] (2) Incubate at room temperature: place the antigen-active membrane strip in the slot, equilibrate at room temperature for 30 minutes, and set the reaction program;

[0046] (3) Immune reaction: 100 μL of serum sample to be tested and 100 μL of sample diluent were manually added to each well, and the well was shaken on an automatic protein blot machine at room temperature for 25 minutes, and then automatically aspirated;

[0047] (4) Washing: Add 800 μL of washing buffer to each tank, shake gently on the automatic protein blot instrument at room temperature for 5 minutes, and remove the liquid in the incubation tank. Repeat the washing twice;

[0048] (5) Antibody incubation: remove the liquid in the incubation tank, add 500 μL of alkaline phosphatase-labeled mouse anti-human Ig E antibody to each tank, shake gently on an automatic Western blot instrument at room temperature for 30 minutes, and then remove it;

[0049] (6) Washing: Add 800 μL of washing buffer to each tank, shake gently on the automatic protein blot instrument at room temperature for 5 minutes, and remove the liquid in the incubation tank. Repeat the washing twice;

[0050] (7) Substrate color development: 500 μL of substrate solution was added to each well and gently shaken on an automatic protein blotting apparatus at room temperature for 25 minutes, and then aspirated;

[0051] (8) Terminate the reaction, add 300 μL of stop solution to each well, shake gently on an automatic protein blot instrument at room temperature for 1 minute, and remove the liquid in the incubation well. Repeat the wash twice;

[0052] (9) Testing: Dry at 37°C for 10 minutes until the membrane surface is completely dry. The instrument automatically reads the results and determines the IgE level of the sample based on the grayscale value.

[0053] Considering the shortcomings of allergen raw material market, such as the batch differences of allergy from natural products, the present invention provides a recombinant dog dander allergen fusion protein. It solves the problem of natural extraction source and batch differences, and uses raw materials to provide a dog dander allergen specific IgE antibody detection kit that can reduce false positives and has high accuracy. The specific implementation is as follows:

[0054] Example 1

[0055] Fusion protein vector construction (dog dander allergen fusion protein gene design)

[0056] (1) The amino acid sequence of dog dander allergens was retrieved from the NCBI database (https: / / www.ncbi.nlm.nih.gov / ).

[0057] (2) Through the above investigation and previous studies, it was determined that dog allergens are four dog dander allergens known to belong to the lipocalin family, Can f 1, Can f 2, Can f 4 and Can f 6, serum albumin Can f 3, arginine esterase Can f 5, rabbit epididymal secretory protein E1 Can f 7, and cysteine ​​protease inhibitor Can f 8.

[0058] (3) Use the bioinformatics analysis software Sopma protein secondary structure prediction website to input and search the above allergen amino acid sequence to obtain the secondary structure prediction results of the allergen protein. Use SWISS-MODEL to predict the three-dimensional structure of the allergen protein, and screen out the dominant sequence based on the allergen antigen index, hydrophilicity, surface accessibility and flexibility prediction results. The selected sequence information is as follows:

[0059] The dominant sequence allergen lipocalin Can f 1 selected the following amino acid sequence:

[0060] QNITVVLHKTSEPGKYTAYEGQRVVFIQPSPVRDHYILYCEGELHGRQIRMAKLLGRDPEQSQEALEDFREFSRAKGLNQEILELAQSET(SEQ ID No. 2);

[0061] The dominant sequence allergen lipocalin Can f2 selected the following amino acid sequence:

[0062] EKVSLTAFKTATSNKFDLEYWGHNDLYLAEVDPKSYLILYMINQYNDDTSLVAHLMVRDLSRQQDFLPAFESVCEDIGLHKDQIVVLSDDDR(SEQ ID No.3);

[0063] The dominant sequence allergen serum albumin Can f3 selected the following amino acid sequence:

[0064] LVDEPQNLVKTNCELFEKLGEYGFQNALLVRYTKKAPQVSPTPTLVEVSRKLGKVGTKCCKKPESERMSCAEDFLSVVLNRLCVLHEKTPVSERVTKCCSESLVNRRPCFSGLEVDETYVPKEFNAETFTFHADLCTLPEAEKQVKKQTA(SEQID No. 4);

[0065] The dominant sequence allergen lipocalin Can f4 selected the following amino acid sequence:

[0066] MRGINVDIPRLKMSFNFYVKVDGECVENSVGASIGRDNLIKGEYNGGNYFRIIDMTPNALIGYDVNVDSKGKITKVALLM(SEQ ID No. 5);

[0067] The dominant sequence allergen arginine esterase Can f5 selected the following amino acid sequence:

[0068] WLGRHNLSESEDEGQLVQVRKSFIHPLYKTKVPRAVIRPGEDRSHDLMLLHLEEPAKITKAVRVMDLPKKEPPLGSTCYVSGWGSTDPETIFHPGSLQCVD(SEQ ID No. 6);

[0069] The dominant sequence allergen lipocalin Can f 6 selected the following amino acid sequence: TKISLICNKTEKDGEYDVVHDGYNLFRIIETAYEDYIIFHLNNVNQEQEFQLMELYGRKPDVSPKVKEKFVRYCQGMEIPKENILDLTQVDR (SEQ ID No. 7);

[0070] The dominant sequence allergen immune epididymal secretory protein E1 Can f7 selected the following amino acid sequence:

[0071] GSAVGVIKELNVNPCPAQPCKLHKGQSYSVNVTFTSNIPSQSSKAVVHGIVLGVAVPFPIPEADGCKSGINCPIQKDKTYSYLNKLPVKNEYPSIKLVVQWMLLGDNNQHLF(SEQ ID No. 8);

[0072] The dominant sequence allergen cysteine ​​protease inhibitor protein Can f8 selected the following amino acid sequence:

[0073] GGLTEAKPATPEVQEIANEVKPQLEEKTNETYQEFEAVEYKTQVVAGINYYIKVRVGDNSYIHLKIF(SEQ ID No. 9);

[0074] Fusion gene design method:

[0075] The genes are arranged in the following order: pel B signal peptide + Can f 1 + (GGGGS) 3 + Can f 2 + (GGGGS) 3 + Can f 4 + (GGGGS) 3 + Can f 6 + (GGGGS) 3 + Can f 7 + (GGGGS) 3 + Can f 8 + (GGGGS) 3 + Can f3 + (GGGGS) 3 + Can f5 + (His) 6 + stop codon (SEQ ID No. 1). The sequences of each dominant allergen are arranged according to the above amino acid sorting order, the pel B signal peptide sequence is added to the N-terminus, the (His) 6 tag is added to the C-terminus, and the flexible peptide gene sequence (Linker sequence) of amino acid residue (GGGGS) 3 is inserted in the middle of each sequence. After optimizing the codons, the above gene fragments (SEQ ID No. 10) are synthesized into the pUC57 cloning vector and named pUC57-Can.

[0076] Example 2

[0077] Construction of recombinant plasmid containing fusion gene:

[0078] (1) The fully synthetic sequence pUC57-Can obtained in Example 1 was amplified by PCR, using Can-F and Can-R primers for amplification, respectively. The PCR cycle program was: denaturation at 94°C for 30 seconds, annealing at 55°C for 20 seconds, and then extension at 72°C for 30 seconds, for a total of 30 cycles. After the last cycle, the reaction tube was incubated at 72°C for 5 minutes to ensure sufficient extension;

[0079] Can-F:CTTTAAGAAGGAGATATACATATGAAGTATCTACTGCCG (SEQ ID No. 11);

[0080] Can-R:GACGGAGCTCGAATTCGGATCCTTAGTGATGATGGTGATGGTGGTCAAC (SEQ ID No. 12);

[0081] (2) Double digestion of the vector pET-22b(+) with restriction endonucleases Nde I and BamH I;

[0082] (3) Using the homologous recombination method, the target fragment and the double-enzyme-cut vector were prepared in a system at a molar ratio of 5:1, reacted at 50° C. for 5 minutes, and immediately cooled on ice;

[0083] (4) The ligation product was transformed into E. coli DH5α competent cells, gently blown to mix, and placed in an ice bath for 30 minutes. Then, the tube was placed in a 42°C water bath for 90 seconds, and the tube was quickly transferred to an ice bath for 120 seconds. 500 μL LB medium was added to each tube, and the tube was shaken and cultured at 37°C, 150 rpm for 60 minutes, and then centrifuged at low speed for 2 minutes.

[0084] (5) Spread on a solid agar plate containing 0.1% ampicillin antibiotic (Amp), culture at 37°C for 15 h, pick a single spot for culture and sequence identification;

[0085] (6) After verification by Sanger sequencing;

[0086] (7) The retained sample was cultured and induced for expression with 0.1 mM IPTG;

[0087] (8) The collected bacteria are ultrasonically disrupted and centrifuged to obtain the supernatant containing the soluble antigen of Can E5 fused to dog dander allergen.

[0088] Example 3

[0089] Prokaryotic expression of Can fusion dog dander allergen protein:

[0090] (1) The Can-positive clone transformed into the OrigamiB (DE3) host was streaked to obtain a single colony, and a single colony was picked into 50 mL LB sterile medium containing Amp resistance and cultured at 37°C, 150 rpm, overnight;

[0091] (2) The next morning, inoculate 1% of the culture into 2 L of LB medium containing Amp resistance, culture at 37°C, 180 rpm until the OD600 nm value reaches 0.6, and then cool to 16°C;

[0092] (3) After the temperature dropped to 16°C, IPTG was added to 0.1 mM and the induction was continued at 16°C and 180 rpm for 12 h;

[0093] (4) Take the fermentation broth after the culture is completed, centrifuge at 4000 rpm and 4°C for 5 minutes, collect the bacterial precipitate, and wash with PBS (10 mM Na 2 HPO 4 , 2mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl, pH 7.4), wash the cells, weigh and record the cell weight, and store at -80°C.

[0094] Embodiment 4:

[0095] Purification and identification of expression products

[0096] (1) Thaw 20 g of the above-mentioned bacterial cells stored at -80°C at room temperature, add 500 ml of disruption buffer (50 mM PB, 300 mM NaCl, 0.5% Triton X-100, pH 8.0) and resuspend, homogenize at 800 Pa, and cycle three times;

[0097] (2) Centrifuge at 12000 rpm, 4°C for 10 min, collect the supernatant and discard the precipitate;

[0098] (3) Take 50 ml of Ni-IDA beads and load it into a 26 mm × 20 cm chromatography column;

[0099] (4) Pre-clean the packing with 10 cv column volume of pure water, then balance with 10 cv of equilibration buffer (50 mM PB, 300 mM NaCl, pH 8.0), and adjust the UV detector to zero; load the above sample onto the chromatography column at a flow rate of 5 ml / min, and collect the flow-through; after loading the sample, balance with 10 cv of equilibration buffer (50 mM PB, 300 mM NaCl, pH 8.0) until the UV detector baseline is stable.

[0100] (5) Wash with 10 cv column volume of washing buffer (50 mM PB, 300 mM NaCl, 30 mM imidazole, pH 8.0) until the baseline of the UV detector is stable;

[0101] (6) Elute the protein with 5 cv column volume of elution buffer (50 mM PB, 300 mM NaCl, 250 mM imidazole, pH 8.0) until the baseline of the UV detector is stable;

[0102] (7) Protein dialysis and storage: The eluted protein was dialyzed to (50 mM PB, 300 mM NaCl, pH 8.0) at a liquid exchange ratio of 1:100, and the liquid was changed every 4 h for a total of 3 times. After the dialysis was completed, the protein was filtered through a 0.22 μm filter membrane and stored at -80°C;

[0103] (8) The target antigen was detected by SDS-PAGE gel electrophoresis. A 12% separation gel and a 5% concentration gel were prepared, and the specific operation was carried out according to the relevant literature; the loading volume of each sample was 10 μL, the electrophoresis voltage in the concentration gel stage was 80 V, and the electrophoresis voltage in the separation gel stage was 120 V. The electrophoresis was performed for 5 hours. After the end, it was stained with Coomassie Brilliant Blue for 5 hours, and then destained for about 12 hours, during which the destaining solution was frequently changed.

[0104] Embodiment 5:

[0105] Determination of protein content of antigen and detection of antigen activity by Western blot:

[0106] (1) Protein quantification using the Bradford method;

[0107] (2) After SDS-PAGE electrophoresis, rinse the separation gel repeatedly in pre-cooled wet transfer buffer for 3 times. Cut off a 0.22 μm PVDF membrane of similar size according to the size of the gel. Balance the filter paper in the wet transfer buffer. The PVDF membrane needs to be activated in methanol for 2 minutes, then rinsed with TBST for 3-5 minutes and balanced in the wet transfer buffer. The membrane is marked in advance and placed in a "sandwich" of cathode-filter paper-gel-membrane-filter paper-anode. Pay attention to the alignment of each interlayer and remove the bubbles in it. Use constant current conditions of 300 mA for transfer for 120 minutes;

[0108] (3) After the transfer is completed, the membrane is removed, treated with TBST, and then immersed in 5% skim milk powder for blocking at 4°C overnight;

[0109] (4) Western Blot Reaction: Sera from 10 patients with dog dander allergy were mixed as positive sera and diluted 1:10 with 1×TBST. After the membrane was blocked overnight, it was washed three times with 1×TBST on a shaker for 10 minutes each time. The membrane was then immersed in the primary antibody mixed serum and incubated on a shaker at room temperature for 2 hours. After that, it was washed three times with 1×TBST. Anti-human Ig E-AP diluted 1:250 was added and reacted on a shaker at room temperature for 1 hour. After the membrane was washed three times with 1×TBST, AP substrate was added and the color was developed in the dark for 10 minutes. The membrane was then soaked in water to terminate the color development reaction. The membrane was photographed on a gel imager to observe the colored reaction bands.

[0110] Embodiment 6:

[0111] Application of Western Blot Kit

[0112] The present invention provides a semi-quantitative kit for detecting dog dander allergen-specific IgE antibodies, which contains the dog dander allergen fusion protein designed and developed above: the kit includes a CCD blocker, a high-activity allergen membrane strip (fusion protein obtained in Example 4), an alkaline phosphatase-labeled mouse anti-human Ig E antibody, a substrate solution, a stop solution, a cleaning solution, and a quality control product. The CCD blocker is MUXF3-human serum albumin, the blocker diluent: contains 50mM Tris-HCl pH 8.0, 20g / L OVA, 0.05g / L Tween-80, 0.18M NaCl, 1% protease stabilizer, 2‰ Proclin-300, and a 20× mother solution with a concentration of 0.3-1.5mg / ml; the high-activity allergen membrane strip is a nitrocellulose membrane coated with a recombinant dog fusion protein, and the coating preparation solution: contains 50mM Tris-HCl pH 8.0, 10g / L OVA, 0.18MNaCl, 1% protease stabilizer, 2‰Proclin-300, the membrane stripping concentration is 0.1-2.0mg / mL; the alkaline phosphatase-labeled mouse anti-human IgE antibody is contained in a 50mM, pH8.0 Tris-HCl buffer, and the content of the anti-human IgE antibody is 10-35μg / mL; the cleaning solution is a 50× concentrated cleaning solution, which is diluted with deionized water at 1:50 when used; the substrate contains 50mM Tris-HCl pH8.0, 1% NBT, 0.1% BCIP, and 2‰Proclin300.

[0113] In a non-limiting embodiment of the present invention, the kit comprises:

[0114] (1) Membrane strips: nitrocellulose membrane coated with recombinant dog dander allergen and quality control line;

[0115] (2) Sample diluent: 50 mM Tris-HCl pH 8.0, 10 g / L OVA, 0.05 g / L Tween-80, 0.18 M NaCl, 1% protease stabilizer, 2‰ Proclin-300, 1× CCD blocker;

[0116] (3) Alkaline phosphatase-labeled mouse anti-human Ig E antibody: 50 mM Tris-HCl pH 8.0, 1% protease stabilizer, containing alkaline phosphatase-labeled mouse anti-human Ig E antibody (10-35 μg / mL);

[0117] (4) Substrate solution: 50 mM Tris buffer pH 8.0, 0.5-1.0% NBT, 0.02-0.3% BCIP, 2‰ Proclin300;

[0118] (5) Concentrated cleaning solution (50×, diluted with deionized water at 1:50 when used): 250 mM Tris buffer pH 8.0, 5% Tween 20, 2% Proclin 300.

[0119] The preparation method of the active membrane strip includes the following 4 steps:

[0120] (1) Membrane strip preparation: stick the cut nitrocellulose membrane onto the double-sided tape and press tightly;

[0121] (2) Preparation of active membrane strips: Prepare recombinant dog fusion protein antigen and dilute it to coating preparation solution (50mM Tris-HCl pH 8.0, 10g / L OVA, 0.05g / L Tween-80, 0.18M NaCl, 1% protease stabilizer, 2‰ Proclin-300), preferably with a stripping concentration of 0.1-2.0mg / mL, quality control products (used to guide the judgment of positive results), respectively diluted with the corresponding coating preparation solution, and used the Shanghai Jie Ning Biotechnology Co., Ltd. stripping gold spraying instrument XYZ3020 for antigen or antibody coating; instrument specifications: 470mm×380mm×395mm. Spray volume: 1μL / mm, striping speed is 60mm / s; after completion, place it under 30-40% humidity conditions to dry for 24h;

[0122] (3) Pasting the active film strip onto a transparent film;

[0123] (4) Cut the pasted polystyrene sheet into 3.0 mm wide reagent strips on an automatic strip cutting machine, and assemble the cut membrane strips.

[0124] Embodiment 7:

[0125] Western blot kit operation process:

[0126] Allergen detection was performed on the immunoblotting platform using the indirect method principle, and the entire reaction was automatically run on an automatic protein blotting instrument.

[0127] (1) Preparation of cleaning solution, alkaline phosphatase-labeled mouse anti-human Ig E antibody, substrate solution, stop solution, and deionized water;

[0128] (2) Incubation at room temperature:

[0129] Place the antigen-active membrane strip in the slot, equilibrate at room temperature for 30 minutes, and set the reaction program;

[0130] (3) Immune response:

[0131] 100 μL of serum sample to be tested and 100 μL of sample diluent were manually added to each slot, and the slot was shaken on an automatic protein blot instrument at room temperature for 25 minutes, after which it was automatically aspirated;

[0132] (4) Cleaning:

[0133] Add 800 μL of washing buffer to each tank, shake gently on the automatic protein blot instrument at room temperature for 5 minutes, and remove the liquid in the incubation tank. Repeat the washing twice;

[0134] (5) Antibody incubation:

[0135] The liquid in the incubation tank was aspirated, and 500 μL of alkaline phosphatase-labeled mouse anti-human Ig E antibody was added to each tank. The cells were gently shaken on an automatic Western blot machine at room temperature for 30 minutes, and then aspirated.

[0136] (6) Cleaning:

[0137] Add 800 μL of washing buffer to each tank, shake gently on the automatic protein blot instrument at room temperature for 5 minutes, and remove the liquid in the incubation tank. Repeat the washing twice;

[0138] (7) Substrate color development:

[0139] Add 500 μL of substrate solution to each well, shake gently on an automatic Western blot instrument at room temperature for 25 minutes, and then aspirate it;

[0140] (8) Reaction termination:

[0141] Add 300 μL of stop solution to each well, shake gently on the automatic protein blot instrument at room temperature for 1 minute, and remove the liquid in the incubation well. Repeat the wash twice;

[0142] (9) Detection:

[0143] Bake at 37℃ for 10 minutes until the membrane surface is completely dry. The instrument automatically reads the result and determines the IgE level of the sample based on the gray value.

[0144] Example 8

[0145] The performance of the immunoblotting kit prepared in Example 7 of the present invention was optimized and evaluated. The specific implementation is as follows:

[0146] (1) Confirmation experiment of the coating concentration of recombinant dog fusion protein antigen

[0147] The recombinant dog fusion protein coating buffer (50mM Tris-HCl pH 8.0, 10g / L OVA, 0.05g / L Tween-80, 0.18M NaCl, 1% protease stabilizer, 2‰ Proclin-300) was streaked at concentrations of 0.1mg / mL, 0.2mg / mL, 0.5mg / mL, 1.0mg / mL, 1.5mg / mL, and 2.0mg / mL, and the corresponding tests were performed. The gray values ​​of 3 positive samples and 2 negative samples of dog dander allergens are summarized in the following Table 1.

[0148]

[0149] (2) Clinical comparison experiment of kit detection

[0150] The recombinant dog dander allergen was fused and expressed, and a kit was formed with the matching reagents to test 42 positive clinical samples and 98 negative samples. The relevant clinical comparison was carried out with the kit for detection by the European Monogram method. The specific data are shown in Table 2 below.

[0151] Table 2 Comparison of consistency between the kit provided by the present invention and the kit for European blotting

[0152]

[0153] This clinical trial was carried out in accordance with the trial plan. Through the assessment of 98 clinical valid samples, the results are shown in Table 2. The control kit detected 42 positive cases, of which 41 were detected as positive by the kit provided by the present application, and 1 was negative. The control kit detected 57 negative cases, of which 57 were detected as negative by the kit provided by the present application, and 1 was positive. It can be seen that the clinical positive compliance rate of the two kits is 97.6%, the negative compliance rate is 98.3%, and the total compliance rate is 98.0%; all of which are greater than the evaluation criteria, indicating that there is no statistically significant difference in the test results between the present invention and the control kit, indicating that the quality of the product of the present invention has reached the quality level of similar products on the market and can meet the needs of clinical trials.

[0154] (3) Batch Difference

[0155] Three batches of fusion expression raw materials were produced, and three batches of reagent kits were used using the three batches of raw materials. The present invention tested 25 positive clinical samples and 10 negative samples. The inter-batch differences of the three batches were within 5% (Table 3), the inter-batch differences were small, and the product quality was stable.

[0156] Table 3 Comparison of differences in batches of kits provided by the present invention

[0157]

[0158]

[0159]

[0160] Figure 1 This is the SDS-PAGE electrophoresis diagram for the expression and identification of the fusion protein before and after induction of dog dander fusion protein; M: Marker, a mixture of proteins with known molecular weights, used to indicate molecular weight and position, 1: whole cell protein before induction of dog dander allergen; 2: whole cell protein after induction of dog dander allergen.

[0161] Figure 2 The results of fusion protein purification; Lane 1: supernatant before column loading; Lane 2: supernatant after column loading; Lane 3: elution with 30 mM imidazole; Lane 4: elution with 250 mM imidazole; M: Maker.

[0162] Figure 3 This is a Western blot verification diagram of the dog dander allergen fusion expression protein; Lane 1: supernatant before column loading; Lane 2: supernatant after column loading; Lane 3: elution with 30mM imidazole; Lane 4: elution with 250mM imidazole; M: Maker.

[0163] The above shows and describes the basic principles, main features and advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and that the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention.

[0164] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A recombinant dog dander allergen fusion protein, characterized in that: The amino acid sequence of the dog dander allergen fusion protein is shown in SEQ ID No.

1.

2. The recombinant dog dander allergen fusion protein according to claim 1, characterized in that: The dog dander allergen fusion protein comprises a dominant sequence allergen lipocalin Can f1, whose amino acid sequence is shown in SEQ ID No.2; a dominant sequence allergen lipocalin Can f2, whose amino acid sequence is shown in SEQ ID No.3; a dominant sequence allergen serum albumin Can f3, whose amino acid sequence is shown in SEQ ID No.4; a dominant sequence allergen lipocalin Can f4, whose amino acid sequence is shown in SEQ ID No.5; a dominant sequence allergen arginine esterase Can f5, whose amino acid sequence is shown in SEQ ID No.6; a dominant sequence allergen lipocalin Can f6, whose amino acid sequence is shown in SEQ ID No.7; a dominant sequence allergen immune epididymal secretory protein E1 Can f7, whose amino acid sequence is shown in SEQ ID No.8; and a dominant sequence allergen cysteine ​​protease inhibitor Can f8, whose amino acid sequence is shown in SEQ ID No.

9.

3. The recombinant dog dander allergen fusion protein according to claim 1, characterized in that: The nucleotide sequence of the recombinant dog dander allergen fusion gene is shown in SEQ ID No.

10.

4. The recombinant dog dander allergen fusion protein and its use according to claim 3, characterized in that: The recombinant expression plasmid of the recombinant dog dander allergen fusion gene nucleotide is pET-22b(+).

5. The recombinant dog dander allergen fusion protein according to claim 4, characterized in that: The expression host used by the recombinant plasmid is Escherichia coli OrigamiB (DE3).

6. The recombinant dog dander allergen fusion protein according to any one of claims 1 to 5, characterized in that: The method for preparing the dog dander allergen fusion protein comprises the following steps: Step (1), synthesizing a dog dander allergen fusion gene; Step (2), after cloning the recombinant plasmid of step (1), constructing the recombinant expression plasmid pET-22b(+)-Can by homologous recombination, and verifying the correctness of its sequence; Step (3), transfecting the recombinant expression plasmid of step (2) into the Escherichia coli expression host OrigamiB (DE3); Step (4), expressing the recombinant dog dander allergen fusion protein in a prokaryotic expression medium using the strain of step (3); Step (5), purifying the bacterial cells of step (4) by nickel column to obtain the recombinant dog dander allergen fusion protein; Step (6), performing protein quantification and activity detection on the recombinant dog dander allergen fusion protein of step (5); Step (7), storing the recombinant dog dander allergen fusion protein of step (6).

7. A use of the recombinant dog dander allergen fusion protein according to any one of claims 1 to 5, characterized in that: The recombinant dog dander allergen fusion protein can be used for dog dander desensitization treatment.

8. The use of the recombinant dog dander allergen fusion protein according to claim 7, characterized in that: The dog dander allergen fusion protein can be applied to immunological diagnostic reagents or allergen detection diagnostic kits.

9. The use of the recombinant dog dander allergen fusion protein according to claim 8, characterized in that: The recombinant dog dander allergen fusion protein can be used to prepare a semi-quantitative dog dander allergen-specific IgE antibody detection kit, which includes a sample diluent containing a CCD blocker, a high-activity allergen membrane strip, an alkaline phosphatase-labeled mouse anti-human Ig E antibody, a substrate solution, a stop solution, a cleaning solution, and a quality control product.

10. The use of the recombinant dog dander allergen fusion protein according to claim 9, characterized in that: The IgE antibody detection kit adopts the indirect method principle to perform allergen detection on an immunoblotting platform, and the entire reaction is automatically run on an automatic protein blotting instrument.

Citation Information

Cited By

  • Canine allergen protein chimeric peptide cCan f 1 as well as coding nucleic acid and application thereof

    CN122381171A